Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease: a meta-analysis

References

• Makhele L, Matlala M, Sibanda M, et al. A cost analysis of haemodialysis and peritoneal dialysis for the management of end-stage renal failure at an academic hospital in Pretoria, South Africa. Pharmacoecon Open. 2019;3(4):631–641.
   PubMed Web of Science ®Google Scholar
• Sato Y, Yanagita M. Functional heterogeneity of resident fibroblasts in the kidney. Proc Jpn Acad Ser B Phys Biol Sci, 2019.95(8):468–478.
   PubMed Web of Science ®Google Scholar
• Blankenburg M, Fett A-K, Eisenring S, et al. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrol, 2019;20(1):171.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Lin J-W, Wu M-S, et al. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis. PLOS One, 2017;12(12):e0188975.
   PubMed Web of Science ®Google Scholar
• Schalekamp MA, Man in't Veld AJ, Wenting GJ. The second Sir George Pickering memorial lecture. What regulates whole body autoregulation? Clinical observations. J Hypertens. 1985;3(2):97–108.
   PubMed Web of Science ®Google Scholar
• Converse RL, Jacobsen TN, Toto RD, Jr., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–1918.
   PubMed Web of Science ®Google Scholar
• Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension, 1995;25(4):878–882.
   PubMed Web of Science ®Google Scholar
• Verdalles U, de Vinuesa SG, Goicoechea M, et al. Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). Nephrol Dial Transplant. 2012;27(Suppl 4):iv31–iv35.
   PubMed Web of Science ®Google Scholar
• Sata Y, Schlaich MP. The potential role of catheter-based renal sympathetic denervation in chronic and end-stage kidney disease. J Cardiovasc Pharmacol Ther, 2016;21(4):344–352.
   PubMed Web of Science ®Google Scholar
• Mancia G. Renal nerve ablation. Eur Heart J. 2018;39(46):4060–4061.
   PubMed Web of Science ®Google Scholar
• Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens. 2011;20(6):647–653.
   PubMed Web of Science ®Google Scholar
• Schmieder RE. Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant, 2020:gfaa237.
   PubMed Web of Science ®Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 2014;14(1):135.
   PubMed Web of Science ®Google Scholar
• Miller JJ. The inverse of the Freeman – Tukey double arcsine transformation. Am Statist. 1978;32(4):138.
   Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al., Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Hering D, Mahfoud F, Walton AS, et al., Renal denervation in moderate to severe CKD. JASN. 2012;23(7):1250–1257.
   Web of Science ®Google Scholar
• Schlaich MP, Bart B, Hering D, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol, 2013;168(3):2214–2220.
   PubMed Web of Science ®Google Scholar
• Ott C, Mahfoud F, Schmid A, et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33(6): p. 1261–1266.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Chen S. Effectiveness of renal sympathetic denervation in renal function and blood pressure in CKD and non-CKD patients with controlled vs. uncontrolled hypertension. Int J Cardiol Heart Vasc. 2016;13:3–5.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Graciano ML, Carreira MAMQ, et al. Long-term effects of renal sympathetic denervation on hypertensive patients with mild to moderate chronic kidney disease. J Clin Hypertens. 2016;18(3):190–196.
   Web of Science ®Google Scholar
• Hameed MA, Freedman JS, Watkin R, et al. Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease. Clin Kidney J. 2017;10(6):778–782.
   PubMed Web of Science ®Google Scholar
• Hering D, Marusic P, Duval J, et al., Effect of renal denervation on kidney function in patients with chronic kidney disease. Int J Cardiol. 2017;232:93–97.
   PubMed Web of Science ®Google Scholar
• Hoye NA, Wilson LC, Wilkins GT, et al. Endovascular renal denervation in end-stage kidney disease patients: cardiovascular protection-a proof-of-concept study. Kidney Int Rep. 2017;2(5):856–865.
   PubMed Web of Science ®Google Scholar
• Ott C, Schmid A, Ditting T, et al. Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. Clin Exp Nephrol. 2019;23(6):749–755.
   PubMed Web of Science ®Google Scholar
• Prasad B, Berry W, Goyal K, et al. Central blood pressure and pulse wave velocity changes post renal denervation in patients with stages 3 and 4 chronic kidney disease: the Regina RDN Study. Can J Kidney Health Dis. 2019;6:205435811982838.
   Google Scholar
• Scalise F, Sole A, Singh G, et al. Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis.J Hypertens. 2020;38(5):936–942.
   PubMed Web of Science ®Google Scholar
• Daemen J, Mahfoud F, Kuck K-H, et al. Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. J Hypertens. 2019;37(9):1906–1912.
   PubMed Web of Science ®Google Scholar
• Kario K, Yamamoto E, Tomita H, et al., on behalf of the SYMPLICITY HTN-Japan Investigators. Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan-safety and efficacy of renal denervation at 3 years. Circ J. 2019;83(3):622–629.
   PubMed Web of Science ®Google Scholar
• Jaén-Águila F, Vargas-Hitos JA, Mediavilla-García JD. Implications of renal denervation therapy in patients with sleep apnea. Int J Hypertens. 2015;2015:408574.
   PubMed Web of Science ®Google Scholar
• Baek SH, Cha R-H, Kang SW, et al. Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. Korean J Intern Med. 2019;34(4):858–866.
   PubMed Web of Science ®Google Scholar
• Wang T-D, Lee Y-H, Chang S-S, et al., 2019 Consensus statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on renal denervation for the management of arterial hypertension. Acta Cardiol Sin. 2019;35(3):199–230.
   PubMed Web of Science ®Google Scholar
• Weber MA, Mahfoud F, Schmieder RE, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv, 2019;12(12):1095–1105.
   PubMed Web of Science ®Google Scholar
• Kannan A, Medina RI, Nagajothi N, et al., Renal sympathetic nervous system and the effects of denervation on renal arteries.World J Cardiol. 2014;6(8):814–823.
   PubMedGoogle Scholar
• Sata Y, Head GA, Denton K, et al. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med. 2018;5:82.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116(6):1007–1021.
   PubMed Web of Science ®Google Scholar
• Norvell JE, Weitsen HA, Dwyer JJ. Degeneration and regeneration of adrenergic nerves in the autotransplanted kidney. Transplantation, 1969;7(3):218–220.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Maia GLM, de Queiroz Carreira MAM, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34(28):2114–2121.
   PubMed Web of Science ®Google Scholar
• Naduvathumuriyil T. et al. Clinical benefits and safety of renal denervation in severe arterial hypertension: a long-term follow-up study. J Clin Hypertens, 2020;22(10):1854–1864.
   Web of Science ®Google Scholar
• Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457–464.
   PubMed Web of Science ®Google Scholar
• Mauriello A, Rovella V, Anemona L, et al. Increased sympathetic renal innervation in hemodialysis patients is the anatomical substrate of sympathetic hyperactivity in end-stage renal disease. J Am Heart Assoc. 2015;4(12):e002426.
   PubMed Web of Science ®Google Scholar
• Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635–643.
   PubMed Web of Science ®Google Scholar
• Miskulin DC, Weiner DE. Blood pressure management in hemodialysis patients: what we know and what questions remain. Semin Dial. 2017;30(3):203–212.
   PubMed Web of Science ®Google Scholar
• Noh MR, Jang H-S, Kim J, et al. Renal sympathetic nerve-derived signaling in acute and chronic kidney diseases. Int J Mol Sci. 2020;21(5):1647.
   Web of Science ®Google Scholar
• Peene B, Benhalima K. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(5):124–136.
   PubMedGoogle Scholar
• Lohmeier TE, Iliescu R, Liu B, et al., Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012;59(2):331–338.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Zhong X, Huang XR, et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther. 2014;22(4):842–853.
   PubMed Web of Science ®Google Scholar
• Meneses GC, Libório AB, de Daher EF, et al. Urinary monocyte chemotactic protein-1 (MCP-1) in leprosy patients: increased risk for kidney damage. BMC Infect Dis. 2014;14(1):451.
   PubMed Web of Science ®Google Scholar
• DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43(2):147–150.
   PubMed Web of Science ®Google Scholar